DELIVERING ON OUR COMMITMENTS
`
`2009 ANNUAL REPORT
`
`Bristol-Myers Squibb
`345 Park Avenue • New York, NY 10154-0037
`212-546-4000 • www.bms.com
`
`This QR-Code can be read with most standard
`Smartphone QR-Code Reader Apps.
`
`ACME-COVER-2009 BMS AR.indd 1
`
`3/8/10 4:59 PM
`
`AstraZeneca Exhibit 2111
`Mylan v. AstraZeneca
`IPR2015-01340
`
`Page 1 of 124
`
`

`
`on the Back cover
`
`Curtis Horne, a law enforcement officer, was
`raised on “all the good things that tasted great.”
`All those “good things” caught up to him one
`day in 2003 when he collapsed from a heart
`attack. Now, Curtis takes his medications and
`does everything that his doctor advises. “I eat
`fruits and vegetables and exercise regularly.
`These are the really ‘good things’ that are good
`for you,” he says. And when he plays with his
`five grandchildren, he thinks, “I almost wasn’t
`here for this.”
`
`At Bristol-Myers Squibb we believe that the
`will of the patient, matched by our desire to
`find breakthrough medicines, can make all the
`difference. For more about Curtis and others
`who are prevailing over serious diseases, visit
`www.bms.com.
`
`Haiti was struck by a catastrophic earthquake on
`January 12, 2010. Within days, Bristol-Myers Squibb,
`its Foundation and its employees were busy helping
`in the relief effort, and by the end of the month had
`donated more than $7 million in cash and products to
`relief organizations on the ground in Haiti. The company
`donated nearly $6.5 million in medicines, including
`antibiotics and analgesics. In addition, the Bristol-Myers
`Squibb Foundation committed more than $600,000 in
`cash, including matching donations for contributions
`from employees in the U.S. and Puerto Rico.
`
`Photo courtesy of the American Red Cross, IFRC/Eric Quintero
`
`Produced by the Bristol-Myers Squibb Communications Department. Copyright © 2010 Bristol-Myers Squibb All rights reserved.
`
`FINANCIAL HIGHLIGHTS
`
`Net Sales
`Dollars in billions
`
`2009
`
`2008
`
`2007
`
`$18.8
`
`$17.7
`
`$15.6
`
`Earnings Per Share
`(from continuing operations attributable to Bristol-Myers Squibb)
`
`GAAP
`
`2009
`
`2008
`
`2007
`
`Non-GAAP
`
`2009
`
`2008
`
`2007
`
`$1.63
`
`$1.35
`
`$0.65
`
`$1.85
`
`$1.49
`
`$1.04
`
`For further detail on management's use of non-GAAP financial
`information and reconciliation of non-GAAP to GAAP EPS, see
`“Management's Discussion and Analysis of Financial Condition
`and Results of Operations – Non-GAAP Financial Measures”
`enclosed and the “Quarterly Package of Financial Information”
`on the company's website at www.bms.com.
`
`Cash, Cash Equivalents and
`Marketable Securities
`Dollars in billions, year ended December 31
`
`2009
`
`2008
`
`2007
`
`$2.6
`
`$9.9
`
`$8.5
`
`cONTENTs
`
`Letter to Our Stockholders
`
`Our Mission and Commitment
`
`Financial Review
`
`Bristol-Myers Squibb Leadership
`
`Stockholder Information
`
`ON ThE cOvER
`
`Gary Smith is a high school athletic director who loves
`the outdoors. In late 2008, he noticed a suspicious mole on
`his left shoulder. It was diagnosed as melanoma, the most
`dangerous form of skin cancer. “I never felt sick,” says Gary,
`“so it was hard for me to grasp the severity of the illness.”
`Despite surgery, however, the cancer spread to his lymph
`nodes, liver and bones. There were few treatment options,
`so his doctor recommended that he enter a clinical trial for
`ipilimumab, an investigational biologic in late-stage clinical
`development. Bristol-Myers Squibb gained the full rights
`to ipilimumab through its acquisition of Medarex, Inc.
`Since entering the trial in April 2009, Gary seems to be
`doing well. “I haven’t slowed down,” he says. One lifestyle
`change, however: “Now I use sunscreen.”
`
`ACME-COVER-2009 BMS AR .indd 2
`
`3/6/10 8:27 AM
`
`Page 2 of 124
`
`

`
`TO OUR STOCkhOLDERS
`
`It is a rare opportunity to be part of something truly transformational.
`Bristol-Myers Squibb is no longer “becoming BioPharma.” We stand
`today as a fully focused and energized BioPharma company, confident
`in our strategy, confident in our people and confident in our culture.
`In 2009, we took three significant steps to complete our transformation:
`• We extended our partnership with Otsuka Pharmaceutical Co., Ltd.,
`thus adding 29 additional months of Abilify sales in the U.S.;
`• We acquired Medarex, Inc., significantly expanding our oncology
`pipeline and biologics capabilities; and
`• We split off our holdings in Mead Johnson Nutrition, creating
`shareholder value and focusing Bristol-Myers Squibb solely
`on biopharmaceuticals.
`And in 2009, we delivered on our commitments. I am pleased to report
`that for the third consecutive year our company has performed well and
`achieved strong financial results with growth in sales and earnings.
`For the year, we posted a 6 percent sales growth, led by our key products such as Plavix, Abilify, Baraclude,
`Orencia, the Sustiva franchise, Sprycel and Reyataz.
`In 2009, net sales from continuing operations were $18.8 billion, compared with $17.7 billion in 2008.
`Diluted net earnings per share from continuing operations were $1.63 in 2009 compared with $1.35 in
`2008, and non-GAAP earnings per share from continuing operations were $1.85 and $1.49, respectively.
`And we ended the year with nearly $10 billion in cash, cash equivalents and marketable securities – funds
`that will enable us to further invest in our future.
`
`James M. Cornelius
`Chairman and Chief Executive Officer
`
`DELIVERING ON OUR COMMITMENTS
`As recently as two years ago, Bristol-Myers Squibb was a traditional diversified midsized pharmaceutical
`and health care products company. As others have merged into megacompanies, we are becoming more
`streamlined and focused. As others have broadened their portfolios, we are focusing on select areas of
`medical need. As others have widened their geographic footprints, we are concentrating on key major
`and emerging markets.
`Today we are a BioPharma leader with a vision for the future. We are leaner, more agile and better able
`to execute our strategy and adapt quickly to change. Our entire organization is focused on a single mission:
`to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
`Our transformation is working. For the past two years, our total return for shareholders, including
`dividends, has been among the best in the industry. We promised to deliver a 15 percent compound
`annual growth rate in our non-GAAP earnings per share from continuing operations from 2007 to 2010,
`and – if we meet our expected 2010 non-GAAP guidance – we are on track to exceed that. We outper-
`formed most mega pharma companies, diversified companies and pure biotech companies, as well as the
`industry average. In December, we announced an increase in the dividend per share of common stock to
`$0.32 per quarter. Reflecting our long-standing commitment to deliver shareholder value,I am proud to
`say that our company has paid dividends to stockholders every single quarter since December 1, 1933.
`We have driven solid, global top-line growth and are doing a good job in managing expenses. We are now
`in a period of growth, which I believe will continue through 2011.
`
`ACME-2009 BMS AR Chairman letter .indd 1
`
`3/6/10 8:53 AM
`
`2009 Annual Report Bristol-Myers Squibb 1
`
`Page 3 of 124
`
`

`
`PRODUCT AND PIPELINE ADVANCES
`In 2009, we gained regulatory approval in the U.S. and Europe for Onglyza, an important new medicine
`for the treatment of type 2 diabetes in adults. Onglyza was discovered by Bristol-Myers Squibb and is
`being developed and marketed in partnership with AstraZeneca. This approval marks the reentry of our
`company into metabolics, an area in which we have a strong legacy and in which we intend to return to
`a leadership position. Following Onglyza – and also with AstraZeneca – we are developing dapagliflozin,
`a potentially first-in-class compound in Phase III clinical development for the treatment of type 2 diabetes.
`
`Since 2002, we have delivered nine important new products, including two biologic medicines. This output Since 2002, we have delivered nine important
`compares favorably to many of our competitors, even those
`whose R&D spend is significantly greater than ours.
`Our pipeline continues to expand. During the past year,
`we increased the number of compounds in Exploratory and
`Full Development by nearly 40 percent. About one-third of
`our compounds in development are biologics.
`We have restructured our collaboration agreement with
`Eli Lilly and Company – originally signed in 2001 with ImClone
`– to include necitumumab, a novel biologic in Phase III
`development for non-small cell lung cancer. We will share
`development and potential commercialization in the U.S.,
`Canada and Japan.
`In September, the U.S. Food and Drug Administration
`accepted the company’s submission of a Biologic License
`Application for belatacept, a promising investigational
`immunosuppressive agent for use in kidney transplantation.
`And following belatacept, we anticipate regulatory submis-
`sions for up to four new drugs through 2012.
`
`pipeline
`
`Bristol-Myers Squibb is dedicated to discov-
`ering and developing innovative medicines
`that address serious unmet medical needs
`in key disease areas. In doing so, we believe
`we can better help patients prevail.
`Compounds in Exploratory Development are
`in preclinical or early clinical development.
`Full Development compounds are investiga-
`tional drugs that are in later-stage clinical
`development or have been submitted to reg-
`ulatory agencies for approval. Finally, medi-
`cines in Marketed Product Development are
`driving current and future growth while also
`undergoing continued clinical development
`to determine whether additional indications
`and formulations will benefit patients.
`
`Disease areas
`
`Cancer
`
`Cardiovascular
`
`immunology
`(including Rheumatoid Arthritis and Solid Organ
`Transplant Rejection)
`
`Metabolics
`(including Diabetes and Obesity)
`
`neuroscience
`(including Psychiatric Disorders and Alzheimer’s Disease)
`
`Virology
`(including HIV/AIDS and Hepatitis)
`
`Each investigational compound is represented
`in the chart as a bar.
`
`exploratory Development
`Full Development
`Marketed product Development
`Pipeline chart as of January 1, 2010.
`
`A FOCUSED STRATEGY
`As we have pursued our BioPharma strategy, we have
`taken steps to reduce the number of our manufacturing
`facilities by approximately 50 percent since 2006, monetized
`our nonpharma businesses and focused on our biopharma-
`ceutical business.
`In February, we executed the highly successful partial IPO
`(initial public offering) of Mead Johnson Nutrition, and we
`split off our remaining holdings of Mead Johnson in December.
`In April, we extended our commercialization agreement
`with Otsuka for Abilify. Our collaboration with Otsuka,
`which had been scheduled to terminate in the U.S. in 2012,
`will now continue until 2015.
`In addition, as a global but focused BioPharma company,
`we are expanding into select emerging markets – those
`that represent significant long-term-growth opportunities.
`Our approach is to successfully develop and commercialize
`select, innovative products in a specific set of key high-growth
`markets – namely, Brazil, Russia, India, China and Turkey.
`
`2
`
`ACME-2009 BMS AR Chairman letter.indd 2
`
`3/8/10 4:51 PM
`
`Page 4 of 124
`
`

`
`PRODUCTIVITY INITIATIVES
`Bristol-Myers Squibb is becoming more agile, entrepreneurial and accountable, and our productivity initia-
`tives are helping fuel those cultural changes. While growing top-line sales and building our pipeline, we are
`reducing our cost base by simplifying our organization, making it more cohesive and efficient. Our produc-
`tivity initiatives are on track to meet or exceed our $2.5 billion cost improvement goal by the end of 2011.
`Today, our productivity improvement is continuous and sustainable. As an example, with funding derived
`from productivity savings in Exploratory Development, the R&D organization is advancing a number of
`early development compounds into Phase I and Phase II development, thus creating more output at the
`same level of spend.
`While overall strategic objectives are still established from a corporate perspective, the business units
`have greater responsibility for determining how to achieve those objectives, and employees have greater
`accountability for their success.
`However, our competitive landscape is constantly changing. World economies are still struggling, generic
`competitors are eroding our Plavix sales in Europe, payer and customer demands are increasing, and it is
`likely that some form of health care reform in the U.S. will impact our company. Therefore, we are taking
`additional steps to identify increased savings in order to deliver our 2010 commitments.
`
`OUR STRING OF PEARLS
`Productivity isn’t just about saving money. To succeed, we need to take our savings and reinvest in our
`future, such as product launches, key product development and our String of Pearls.
`In 2007, with the purchase of Adnexus Pharmaceuticals, we launched our String of Pearls initiative
`of innovative alliances, partnerships and acquisitions. Each transaction is highly strategic, designed to
`
`enhance our own internal capabilities and targeted to fit within our overall strategy. enhance our own internal capabilities and targeted to fit within our overall strategy.
`For instance, we have made a strategic decision to return to
`a leadership position in oncology based on a strong legacy in
`cancer medicines dating back 40 years. Our current portfolio
`includes three key products – Erbitux, Sprycel and Ixempra –
`and we have a robust pipeline of innovative medicines in
`development. To further enhance our position, in August
`we acquired Medarex, Inc., for $2.3 billion.
`In 2009, we also entered into global collaborations with
`ZymoGenetics, Nissan Chemical Industries and Teijin
`Pharma, and Alder Biopharmaceuticals. In early 2010,
`we entered into a global collaboration with Allergan. Our
`full array of 10 pearls encompasses many of our key disease
`areas, including cancer, cardiovascular disease, immunology,
`neuroscience and virology.
`
`COrpOraTe CiTiZensHip
`
`Bristol-Myers Squibb has been recognized
`for corporate citizenship and sustainability.
`Among our 2009 honors and recognitions:
`
`• #1 Best Corporate Citizen by Corporate
`Responsibility Officer magazine;
`
`• Awarded the Allicense Breakthrough
`Alliance Award, which honors the world’s
`most innovative biotech and pharma part-
`nerships, for the second year in a row;
`
`• Ranked eighth among 500 of America’s
`largest corporations in Newsweek’s
`Green Ranking;
`
`BUILDING ThE FUTURE
`We’ve accomplished a lot, but challenges remain.
`Our chief concerns are patent expirations beginning in
`2012 in the U.S. with Plavix and Avapro. By reining in costs,
`rationalizing our manufacturing network and advancing our
`new products, we are now fundamentally better off. Thanks
`to all of our BioPharma initiatives – including the extension
`of our collaboration with Otsuka – we have transformed
`
`• 40th among 100 of the world’s most
`respected companies ranked by Barron’s
`magazine; and
`
`• Included on the Dow Jones Sustainability
`Index as among the leading sustainability-
`driven companies.
`
`2009 Annual Report Bristol-Myers Squibb 3
`
`ACME-2009 BMS AR Chairman letter .indd 3
`
`3/6/10 8:53 AM
`
`Page 5 of 124
`
`

`
`what was previously thought of as a cliff
`in 2012 and 2013 to a more manageable
`plateau on which we can create a platform
`for future growth.
`For whatever lies ahead, we are in a much
`stronger position – and better prepared to
`build our next period of growth projected for
`2014 and beyond.
`
`On March 2, 2010, Bristol-Myers Squibb
`announced that Lamberto Andreotti (left),
`president and chief operating officer, will
`become chief executive officer, effective
`May 4, 2010. Jim Cornelius will remain
`chairman of the board. “Lamberto has
`demonstrated extraordinary leadership as
`president and chief operating officer,” said
`Mr. Cornelius. “He is the ideal candidate to
`lead the company as we move forward with
`our BioPharma strategy.” Mr. Andreotti has
`been with Bristol-Myers Squibb for 12 years
`in senior leadership roles, both in the U.S.
`and internationally.
`
`OUR MISSION AND COMMITMENT
`Bristol-Myers Squibb has transformed. But
`we have never swayed from our commitment
`to our patients.
`Curtis Dunaway is one such patient. In 2007, at
`age 39, Curtis was suffering from kidney failure.
`“I was on the verge of knocking at death’s door,”
`he says. He received a transplant and was given
`immunosuppressant drugs, but the side effects
`left him increasingly shaky, restless and sleep
`deprived. Then researchers at the University
`of California, San Francisco, Medical Center
`asked him if he’d like to enter a clinical trial for
`belatacept. He did, and Curtis has responded
`well. “With the grace of God, my life has liter-
`ally been given back to me,” he says. “No words
`can express my appreciation and gratitude.”
`It is for patients like Curtis that Bristol-Myers
`Squibb employees come to work every day.
`To better reflect Bristol-Myers Squibb as we are
`today – and with input from employees worldwide and the approval of the Management Council
`and the Board of Directors – we have redefined our company’s mission statement and created a new
`Mission and Commitment (featured in a special section beginning on the facing page).
`Now, our Mission is a succinct 14 words: “To discover, develop and deliver innovative medicines that
`help patients prevail over serious diseases.” This Mission clearly sets us apart as a company dedicated
`to providing medicines that address unmet medical needs.
`We have transformed our company, delivered on our commitments and set a course for the future.
`This would not have been possible without unflagging dedication and innovation by our employees
`and counsel and support by our Board of Directors. To be sure, there are challenges ahead. But I have
`every confidence that we are now prepared to face them head-on and to emerge stronger than ever.
`
`James M. Cornelius
`Chairman and Chief Executive Officer
`March 9, 2010
`
`4
`
`ACME-2009 BMS AR Chairman letter .indd 4
`
`3/6/10 8:53 AM
`
`Page 6 of 124
`
`

`
`our mission
`
`To discover, develop and deliver innovative medicines
`that help patients prevail over serious diseases.
`
`ACME-2009 BMS AR .indd 5
`
`3/6/10 8:47 AM
`
`Page 7 of 124
`
`

`
`Charlotte Gillis started feeling tired all the time. She
`was also thirsty and gained weight inexplicably. “I thought
`I just needed some vitamins.” When she was diagnosed
`with type 2 diabetes, she says, “I was relieved to know
`what I was facing.” But even with diet, exercise and
`medication, her blood glucose levels went up. She tried a
`lot of medications, but none seemed to work. In Septem-
`ber 2009, her doctor prescribed Onglyza (saxagliptin),
`approved by the U.S. Food and Drug Administration for the
`treatment of type 2 diabetes in adults. Since then, and by
`continuing her diet, says Charlotte, her blood sugar levels
`are under better control. “I feel great about doing all I can
`to fight my diabetes,” she says.
`
`6
`
`ACME-2009 BMS AR .indd 6
`
`3/6/10 8:47 AM
`
`Page 8 of 124
`
`

`
`TO OUR
`PATIENTS &
`CUSTOMERS
`
`We commit to scientific excellence and investment in biopharmaceutical research
`and development to provide innovative, high-quality medicines that address the
`unmet medical needs of patients with serious diseases. We apply scientific rigor to
`produce clinical and economic benefit through medicines that improve patients’ lives.
`We strive to make information about our medicines widely and readily available.
`
`Around the world, Bristol-Myers Squibb medicines help millions of patients in their
`fight against serious diseases such as cancer, heart disease, diabetes, HIV/AIDS,
`rheumatoid arthritis, hepatitis B and psychiatric disorders.
`
`“Since 2002, we’ve introduced nine important new products, including both biologics
`and small molecules,” says Elliott Sigal, M.D., Ph.D., chief scientific officer and presi-
`dent, Research and Development. “Many more innovative potential new medicines,
`focused on areas of serious unmet medical needs, are being studied in preclinical and
`clinical trials worldwide and are advancing through our R&D pipeline.”
`
`“As a BioPharma leader, we are also committed to scientific analysis that shows how
`the appropriate use of medicines can improve health outcomes and deliver value for
`individual patients,” says Lamberto Andreotti, president and chief operating officer.
`“We are working in new ways with physicians, payers, patients and other key stake-
`holders to deliver tailored and timely information that helps them utilize our medicines
`in the most appropriate and effective manner.” Our policy also calls for the open and
`timely reporting of clinical trial results for our marketed products, regardless of outcome.
`
`What sets us apart? At Bristol-Myers Squibb, we believe it’s our commitment to help
`patients prevail over serious diseases and our focus on finding innovative medicines
`that combat those diseases.
`
`Richard J. Migliori, M.D., is executive vice
`president and chief medical officer of Enterprise Services
`Group at UnitedHealth Group. “The role of the pharma-
`ceutical company in improving the performance of the
`health care system is undeniable. In fact, it’s vital,” he
`says. “We turn to the pharmaceutical companies to ask
`what they have that’s going to change the face of health
`care in making it safer, making it more timely, making it
`more effective, making it more efficient, making it more
`equitable and making it more patient centered. Bristol-
`Myers Squibb has done an outstanding job of being one
`of the first to the table to help us understand the impact
`of what their agents can do in terms of improving the
`performance of the health care system and giving people
`access to high-quality health care they can afford.”
`
`2009 Annual Report Bristol-Myers Squibb 7
`
`ACME-2009 BMS AR.indd 7
`
`3/9/10 11:11 AM
`
`Page 9 of 124
`
`

`
`TO OUR
`EMPLOYEES
`
`
`
`Myriam Exumé joined Bristol-Myers Squibb in 2000 as a newly minted M.B.A.
`interested in marketing. She was also a single mom. Myriam enrolled her then 4-year-
`old son in on-site day care, and with support from the company’s mentoring program
`and other career development opportunities, she says, “I found that I can achieve a
`work-life balance as a mom and succeed as a marketer.” She advanced to marketing
`director. But in February 2009, she was diagnosed with cancer. “It was frightening,”
`she says. Thanks in part to a Bristol-Myers Squibb medication — and support by her
`family, friends and colleagues — Myriam is doing well. “I have a new appreciation for
`life, for work and for what medicines can do to help patients prevail.”
`
`We embrace a diverse workforce and inclusive culture. The health, safety, professional
`development, work-life balance and equitable, respectful treatment of our employees
`are among our highest priorities.
`
`At Bristol‑Myers Squibb, innovation is critical for successfully executing our
`BioPharma strategy. That innovation is enhanced by our diverse workforce and
`an inclusive culture that encourage unique perspectives and new ideas.
`
`“Leveraging diversity inspires creativity and innovation and frankly, from a business
`perspective, enables us to better meet the unique needs of our customers,” says
`Anthony C. Hooper, president, Americas.
`
`We are committed to a workforce that reflects the diversity of our patients and
`customers, our shareholders and the communities where we live and work. We
`view diversity in the broadest sense – including age, ethnicity, gender, appearance,
`race, physical abilities, religion, social-economic background, political affiliation,
`sexual orientation, thinking styles, life experiences and other areas of diversity.
`
`Bristol-Myers Squibb has been hailed year after year as one of the best companies
`for women, female executies and working parents, as well as a great place for scientists.
`We’ve also been recognized by the Human Rights Campaign Foundation’s Corporate
`Equality Index for achieving a perfect score for the past four consecutive years.
`
`8
`
`ACME-2009 BMS AR .indd 8
`
`3/6/10 8:48 AM
`
`Page 10 of 124
`
`

`
`TO OUR
`GLOBAL
`COMMUNITIES
`
`We promote conscientious citizenship that improves health and promotes sustainability
`in our communities.
`
`All too often, patients worldwide face
`barriers to health care. And certain
`populations – particularly the urban
`and rural poor, women, racial and
`ethnic minorities, and marginalized
`people – experience worse health
`outcomes compared with others.
`
`The Bristol-Myers Squibb Foundation
`seeks to address those health disparities.
`The Foundation has targeted the follow-
`ing diseases and regions:
`
`• HIV/AIDS in Africa, where the
`AIDS pandemic continues to spread;
`
`• Hepatitis in Asia, where millions are
`chronically infected with hepatitis
`B and C;
`
`• Cancer in central and eastern Europe,
`where access to cancer education,
`treatment, prevention and care is
`especially needed; and
`
`• Type 2 diabetes and serious mental
`illness in the U.S., where underserved
`populations often need access to care
`and support.
`
`The model for these programs is Bristol-
`Myers Squibb’s groundbreaking SECURE
`THE FUTURE. This $150 million program,
`established in 1999 to help confront HIV/
`AIDS in Africa, has funded more than 240
`projects in 20 African countries, integrating
`clinic-based medical care with community-
`based health education and supportive care.
`
`“In all of our programs, we’re working to
`help reduce health disparities by strengthen-
`ing community-based health care worker
`capacity and integrating medical care and
`community-based supportive services,” says
`John Damonti, vice president, Corporate
`Philanthropy, and president, Bristol-Myers
`Squibb Foundation. “In short, we’re mobiliz-
`ing communities in the fight against disease.”
`
`The Shanghai Charity Foundation
`is an innovative and pioneering program that is
`leading efforts to educate those most at risk for
`hepatitis and to counter misinformation, fear
`and stigma. This initiative, which is supported by
`Bristol-Myers Squibb Foundation’s Delivering
`Hope program, is training 10,000 migrant workers
`to provide information in hospitals about hepatitis
`B awareness and prevention. “People think that
`only medicine, doctors and hospitals can help fight
`serious disease,” says Kitty Xia, Shanghai Charity
`Foundation executive deputy secretary-general.
`“Education is just as important.”
`
`2009 Annual Report Bristol-Myers Squibb 9
`
`ACME-2009 BMS AR .indd 9
`
`3/6/10 8:48 AM
`
`Page 11 of 124
`
`

`
`TO OUR
`SHAREHOLDERS
`
`We strive to produce sustained strong performance and shareholder value.
`
`Bristol-Myers Squibb has successfully
`transformed into a BioPharma company.
`As such, we are focused on building
`sustainable leadership by providing
`innovative medicines that address
`serious medical needs. Our financial
`performance is driven by established
`market leaders – Plavix, Abilify, Reyataz,
`Erbitux and Sustiva/Atripla – comple-
`mented by recent launches – Baraclude,
`Orencia, Sprycel, Ixempra and Onglyza–
`and enhanced by continuous improve-
`ment initiatives.
`
`In addition, our pipeline is recognized as
`one of the most productive in the indus-
`try, one that we expect will drive our
`company’s growth over the next decade.
`
`“In short, we are delivering on our
`commitments,” says Charles Bancroft,
`acting chief financial officer. “We have
`a strong balance sheet, we’re increas-
`ing productivity, we’ve successfully
`executed complex projects such as the
`Mead Johnson IPO and split-off, and
`we’re delivering on our String of Pearls
`strategy of innovative alliances, partner-
`ships and acquisitions. Taking all these
`components together, I believe we are
`building a very solid base for the future.”
`
`And at all times, we are aware of our
`true bottom line: Our success as a
`BioPharma company is measured by
`the difference we can make in the lives
`of patients fighting serious diseases.
`
`Dolly Dunklin Marting is maintaining a family tradition. Nearly a century ago, her great
`grandmother invested household money in a fledgling company. The family held on to the stock for
`five generations … and that company became Bristol-Myers Squibb. “I’m a great believer in our com-
`pany,” says Dolly, who has continued the legacy by passing along BMY stock to her grown children.
`When severe mental disability touched her family, Dolly became acutely aware of the needs of this
`fragile population. BMY enables her to support the Anderson Center for Autism in Staatsburg, New
`York. “My dividends provide the operating capital needed to help enhance the lives of profoundly
`handicapped children,” she says. “BMY makes my passion a reality.”
`
`10
`
`ACME-2009 BMS AR.indd 10
`
`3/8/10 4:54 PM
`
`Page 12 of 124
`
`

`
`TO OUR
`ENVIRONMENT
`
`Roberta Ercole is proud of Bristol-Myers Squibb’s innovative efforts to reduce the
`impact on the environment at our manufacturing facility in Anagni, Italy. “Our solar panel
`project is just one way that we can be an example for our employees and the people of
`Anagni,” says Roberta, Environment, Health and Safety manager. “Since the installation
`of a photovoltaic plant, employees have asked us for information on how they can install
`similar panels for their homes — and some already have.” For Roberta and her colleagues,
`it’s more than conserving resources: “It’s about saving our environment, our home.”
`
`We encourage the preservation of natural resources and strive to minimize the
`environmental impact of our operations and products.
`
`“For us, being green is more than just meeting environmental mandates,” says Susan Voigt,
`vice president, Environment, Health, Safety and Sustainability. “It’s about taking action
`that incorporates conservation and innovation across broad aspects of our business.”
`
`At many of our facilities worldwide, Bristol-Myers Squibb is integrating comprehensive
`energy management, pollution controls and other practices to reduce environmental
`impacts. For example, in Devens, Massachusetts, the laboratory and administrative
`building of our $750 million facility has already received gold-level certification by the
`Leadership in Energy and Environmental Design system. The manufacturing suite is
`expected to be the first biologics facility to become LEED certified. And in Anagni, Italy,
`where such medicines as Sprycel and Baraclude are packaged, more than 480 square
`meters of rooftop solar panels provide power and reduce greenhouse gas emissions.
`
`Going green has many advantages. Along with energy savings and environmental
`benefits, green buildings provide satisfying work environments, which in turn promote
`greater efficiency and productivity.
`
`Newsweek’s 2009 Green Ranking recognized Bristol-Myers Squibb as eighth among 500
`of the largest U.S. corporations. And Bristol-Myers Squibb was included in the 2009 Dow
`Jones Sustainability North America Index of leading sustainability-driven companies.
`
`2009 Annual Report Bristol-Myers Squibb 11
`
`ACME-2009 BMS AR.indd 11
`
`3/8/10 4:54 PM
`
`Page 13 of 124
`
`

`
`OUR
`MISSION
`
`To discover, develop and deliver innovative medicines
`that help patients prevail over serious diseases.
`
`OUR COMMITMENT
`
` To our patients and customers, employees, global communities, shareholders,
`environment and other stakeholders, we promise to act on our belief that the priceless
`ingredient of every product is the integrity of its maker. We operate with effective
`governance and high standards of ethical behavior. We seek transparency and dialogue
`with our stakeholders to improve our understanding of their needs. We take our
`commitment to economic, social and environmental sustainability seriously, and
`extend this expectation to our partners and suppliers.
`
`To our patients and customers
`
` We commit to scientific excellence and investment in biopharmaceutical research and
`development to provide innovative, high-quality medicines that address the unmet
`medical needs of patients with serious diseases. We apply scientific rigor to produce
`clinical and economic benefit through medicines that improve patients’ lives. We strive
`to make information about our commercialized medicines widely and readily available.
`
`To our employees
`
` We embrace a diverse workforce and inclusive culture. The health, safety, professional
`development, work-life balance and equitable, respectful treatment of our employees
`are among our highest priorities.
`
`To our